EUVIMEDEUVIMED entdecken
Leserbrief

Sarcopenia as a Preclinical Marker of Inflammatory Bowel Disease: Functional Muscle Loss, Disease Subtypes, and Clinical Modifiers

Guangzhi Ying iD, Xiaoxia Chen

Geriatrics & Gerontology International · 2026-06 · 26 (6)

DOI: 10.1111/ggi.70569 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Geriatrics & Gerontology International, online erschienen am 31.05.2026. Verfasst von Guangzhi Ying und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Xianju People's Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People's Hospital, Affiliated Hospital of…. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with great interest the large prospective cohort study by Zhang et al. examining whether baseline sarcopenia predicts incident inflammatory bowel disease (IBD) in UK Biobank participants [1]. The authors reported that confirmed sarcopenia, particularly severe sarcopenia, was associated with a higher long-term risk of IBD and ulcerative colitis (UC), whereas low grip strength alone was associated with increased risk across IBD subtypes. This is an important and timely contribution. We would like to raise several methodological and clinical considerations that may further strengthen the interpretation of these findings and guide future work [2, 3]. First, the finding that low grip strength was associated with incident IBD is clinically meaningful, but it also raises the question of whether muscle function is acting as a marker of broader vulnerability rather than isolated muscle disease. The EWGSOP2 consensus identifies low muscle strength as the key criterion for probable sarcopenia and notes that it may precede measurable loss of muscle mass [2]. In this context, grip strength may reflect frailty, chronic low-grade inflammation, and reduced nutritional reserve, all of which are relevant to IBD development. At the same time, grip strength is influenced by comorbid conditions such as osteoarthritis, neurologic impairment, pain, and general illness burden, which may not be fully captured in the present analysis. Therefore, the observed association may partly reflect functional vulnerability rather than sarcopenia per se. Prospective studies incorporating repeated muscle assessments, performance-based tests, and inflammatory biomarkers would be valuable to determine whether the association persists after more detailed phenotyping [3, 4]. Second, the more pronounced association with UC than Crohn's disease (CD) deserves careful interpretation. UC and CD differ substantially in their immunopathology, tissue distribution, and mucosal barrier involvement; therefore, the observed heterogeneity may indicate disease-specific mechanisms rather than a uniform effect of sarcopenia on intestinal inflammation [5]. From a clinical perspective, UC may be more closely linked to systemic inflammatory burden and mucosal barrier dysfunction, both of which overlap with sarcopenia-related pathways such as altered gut permeability, cytokine activation, and nutritional depletion. However, the study did not include baseline inflammatory or nutritional markers such as C-reactive protein, albumin, hemoglobin, vitamin D status, or unintentional weight loss. These factors could either confound the association or lie on the causal pathway. In particular, individuals with declining grip strength and subtle nutritional compromise may already be in a preclinical inflammatory state before IBD is diagnosed. Inclusion of longitudinal biomarker data would help clarify whether sarcopenia is an independent risk factor or an early clinical marker of occult disease [4, 5]. Third, several additional clinical modifiers may have influenced the observed associations but were not fully explored. Medication exposure beyond NSAIDs, including corticosteroids, proton pump inhibitors, statins, metformin, and biologic or immunomodulatory agents, may affect both muscle metabolism and IBD risk. Likewise, physical inactivity, obesity-related sarcopenia, frailty, and smoking may cluster together and jointly shape immune and metabolic risk. Given that sarcopenia is a heterogeneous clinical syndrome, subgroup analyses incorporating body composition phenotypes, frailty indices, and medication data would improve interpretability and may identify patients at particularly high risk. Such analyses would also help determine whether the association is driven by sarcopenia itself or by a broader chronic disease phenotype [2, 3]. In summary, this study provides valuable population-level evidence that impaired muscle strength, rather than muscle quantity alone, is associated with future IBD risk, particularly UC. Clarifying the roles of functional muscle loss, occult inflammation, and additional clinical modifiers will be essential for understanding causality and for translating these observations into prevention strategies. We commend the authors for addressing this underexplored link and encourage further longitudinal studies with richer phenotyping to determine whether sarcopenia is a modifiable risk state for IBD. The authors have nothing to report. The authors have nothing to report. The authors declare no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Autor:innen und Institutionen

  • Department of Internal Medicine, Xianju People's Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People's Hospital, Affiliated Hospital of Hangzhou Medical College, Xianju, Zhejiang, China.

ORCID-Profile: Guangzhi Ying

Zitieren

APA

Ying, G., & Chen, X. (2026). Sarcopenia as a Preclinical Marker of Inflammatory Bowel Disease: Functional Muscle Loss, Disease Subtypes, and Clinical Modifiers. Geriatrics & Gerontology International, 26(6). https://doi.org/10.1111/ggi.70569

Vancouver

Ying G, Chen X. Sarcopenia as a Preclinical Marker of Inflammatory Bowel Disease: Functional Muscle Loss, Disease Subtypes, and Clinical Modifiers. Geriatrics & Gerontology International. 2026;26(6). doi:10.1111/ggi.70569

BibTeX
@article{Ying2026,
  author = {Ying, Guangzhi and Chen, Xiaoxia},
  title = {Sarcopenia as a Preclinical Marker of Inflammatory Bowel Disease: Functional Muscle Loss, Disease Subtypes, and Clinical Modifiers},
  journal = {Geriatrics & Gerontology International},
  year = {2026},
  volume = {26},
  number = {6},
  doi = {10.1111/ggi.70569}
}
Kostenlos starten →